Aquestive Misled on Prospects of Sublingual Drug, Investor Says

Aquestive Therapeutics Inc. made misleading statements about the progress of its FDA application for a new sublingual drug for anaphylaxis, an investor alleges in a suit filed Thursday.

Aquestive and its top executives made “overwhelmingly positive statements” to investors, Vincent Modica says in the proposed class action filed in the US District Court for the District of New Jersey. But the company “concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling,” Modica says.

Aquestive announced delays Jan. 9, saying the Food and ...